FIGURE 6 from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

figure

posted on 2023-08-15, 14:20 authored by Junkai Wang, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt, Meggie N. Young, Mothaffar F. Rimawi, Foluso O. Ademuyiwa, Meenakshi Anurag, Beom-Jun Kim, Matthew J. Ellis

The relationship between the KIPA-based PBP signature score, immune scores, and immune checkpoint levels. A, Scatter plot shows the correlation between the KIPA-based PBP signature score and mRNA-based immune scores (from ESTIMATE, Cibersort, and xCell). EST: ESTIMATE, CS: Cibersort, xC: xCell. B, Scatter plot shows the correlation between the KIPA-based PBP signature score and protein-based immune modulator stimulatory or inhibitory scores. C, Scatter plot shows the correlation between the KIPA-based PBP signature score and PD-L1 CPSs from IHC staining. D, Scatter plot shows the correlation between the KIPA-based PBP signature score and PD-L1 phosphoprotein levels.

Funding

HHS | NIH | National Cancer Institute (NCI)

Cancer Prevention and Research Institute of Texas (CPRIT)

History

ARTICLE ABSTRACT

The identification of pretreatment predictive biomarkers for pCR in response to neoadjuvant chemotherapy would advance precision treatment for TNBC. To complement standard proteogenomic discovery profiling, a KIPA was deployed and unexpectedly identified a seven-member non-kinase PBP pCR-associated signature. Individual members served diverse pathways including IFN gamma response, nuclear import of DNA repair proteins, and cell death.